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Abstract 
INTRODUCTION: Microsatellite instability (MSI) is the genetic pathway underlying 15% of sporadic colorectal 
carcinoma (CRC) and hereditary non-polyposis CRC. MSI-H CRC has a distinct clinicopathological characteristic 
including excess mucin and signet ring component, proximal colon, Crohn’s like reaction, lymphocytic infiltration, 
and better survival.  
AIM: This research aims to screen Egyptian CRC patients for MSI status by IHC testing of expression of the MMR 
proteins in correlation to its clinicopathological features. 
MATERIAL AND METHODS: Immunohistochemistry study for mismatch repair proteins (MMR) was done on 115 
cases of CRC. Their expressions were assessed and correlated to clinicopathological parameters in an attempt to 
obtain the most significant predictors of MSI.  
RESULTS: MSI (low and high) represents 67% of the study cases. The most frequent expression pattern was 
combined loss of MLH, and PMS2 (38% of MSI) followed by a combined loss of MSH2, and MSH6 (29% of MSI). 
There was significant correlation of expression pattern of MMR proteins with the laterality, lymphovascular emboli, 
perineural invasion, grade, T stage, N stage, signet ring component, tumor infiltrating lymphocyte, and peritumoral 
lesion (0.014, 0.035, 0.012, 0.033, 0.013, 0.000, 0.041, 0.012, and 0.009 respectively). Proximal location (right 
sided) and lower grade, higher nodal stage, and marked TIL were selected as predictors of MS-H CRC (0.005, 
0.031, 0.025, and 0.000 respectively). 
CONCLUSION: All clinicopathological and histological parameters should be assessed in CRC for the sake of 
predicting MSI. The optimal approach to MSI evaluation is (IHC) assessment of MMR proteins. 
 
 
 
 
Introduction 
 
 Colorectal cancer (CRC) is the most 
commonly observed cancer worldwide [1]. It is one of 
the most common cause of cancer-related death 
worldwide [2]. Cancer colon, as any cancer is caused 
by environmental and genetic factors [3]. 75% of 
cancer colon is sporadic and the remaining 30% has a 
hereditary contribution [4]. Hereditary CRC is 
appeared in two forms. The first is preceded by 
familial adenomatosis polyposis (FAP). The second is 
Lynch syndrome (LS) that has a defect in mismatch 
repair (MMR) gene and often referred to as hereditary 
nonpolyposis colorectal cancer. However, there was 
another category that exhibit gathering of CRC and/or 
adenomas in families with an identifiable hereditary 
syndrome, and are known as familial CRC. The 
genetic basis of familial CRC remains unknown [5], 
[6]. 
 There are two molecular genetic pathways 
that underlie colorectal carcinogenesis. The first 
pathway is chromosomal instability that involves the 
activation of proto-oncogenes such as K-ras, and 
inactivation of tumour-suppressor genes, such as 
APC, TP53, DCC, SMAD2, and SMAD4 [7], [8]. 
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Chromosomal instability occurs in 85% of sporadic 
CRC and FAP [9]. The second pathway is the 
microsatellite instability (MSI) mutational pathway. 
MSI results from inactivation, mutational and/or 
epigenetic silencing of mismatch repair (MMR) [8], 
[10], [11]. MSI is not limited to hereditary non-
polyposis cancer colon (HNPCC ) but also present in 
sporadic CRC [9], [11]. 
 The genetic basis for instability in MSI 
tumours is an inherited germline alteration in any one 
of the five human MMR genes: MLH, MSH2, MSH6, 
PMS2, and PMS1 [8], [12]. More specifically, germline 
mutations in MSH2 and MLH1 are responsible for 
most HNPCC families, while MSH6 is less common 
and PMS2 and PMS1 are rare [8]. MSI can be present 
in 10-15% of sporadic colorectal carcinoma. Acquired 
hypermethylation of MLH1 promotor and subsequent 
transcriptional silencing is the cause of high MSI in 
sporadic CRC [8], [9], [13]. 
 Abnormal expression of MMR in CRC may be 
due to complete loss of expression, expression of an 
only truncated protein that does not bind to the 
antibody or weak /patchy cytoplasmic reaction if the 
mutation forms premature truncated but stable protein 
[14].  
 Hashmi et al., 2017 reported that MSI-H 
cancers often stimulate a host response that leads to 
migration of activated T cells into tumour cells. T cell 
cytotoxicity is activated. The T cells are CD8+, TCR+ 
cells. Therefore improved prognosis of MSI-H colonic 
cancers is related to the upregulated immune system 
that prevents the emergence of metastatic deposit [9]. 
 There were distinct clinicopathological 
characteristics of CRC with MSI. These include poor 
differentiation, excess mucin and signet ring 
component, proximal colon, medullary feature, 
Crohn’s like reaction and lymphocytic infiltration [9]. It 
is noted that the survival rate of CRC with high MSI is 
better when it is compared with MSS tumour 
evidenced by in tumoral lymphocytosis of MSI 
tumours [9], [15]. However, it sometimes associated 
with metachronous cancer and resistant to traditional 
chemotherapeutic agent [16], [17]. 
 Investigation for the presence of MSI in CRC 
is really important due to many factors. It decides the 
extent of surgical treatment, the prophylactic surgery 
of hysterectomy and oophorectomy, and screening of 
the family member for the presence of the same 
mutation [9], [18]. Recognition of MSI phenotype can 
be done by histopathology and IHC because of CRC 
with MSI shares morphological features such as 
young patient age, right-sided location, mucinous and 
signet ring histology and intratumoral lymphocytosis. 
This fact allows the pathologist to dispense on PCR 
which remains the gold standard for recognition of 
MSI phenotype as it is not practicable and expensive 
in routine pathology lab [9], [15], [19]. 
 Our study aims to screen CRC patients for 
MSI status in a big histopathology lab in Egypt 
(Referral lab for a big sector of Egyptian population) 
by immunohistochemical testing of expression of the 
MMR proteins and its relation to the 
clinicopathological features in CRC patients. 
 
 
Material and Methods 
 
 A group of 115 cases of CRC were conducted 
in the present study. They were retrieved 
consecutively from the archives of Professor Elia, Anis 
Ishak Laboratory Pathology Centre (Cairo, Egypt), 
from 2015 to 2018. One representative slide of all 
cases were retrieved and reviewed. Then, the 
allocated paraffin-fixed tissue blocks were selected 
that showed both tumour and adjacent non-tumor 
colonic epithelium. The clinical and pathological 
information as patient’s age, gender, tumour laterality 
(the right side from cecum to splenic flexure), 
lymphovascular invasion, perineural invasion, T stage, 
and N stage were obtained from the records. The 
cases were grouped according to the age of 2 groups 
(< 50, ≥ 50). 
 
 Histopathology 
 The histopathological features of each slide 
were reviewed by 3 pathologists as regard the 
variants (mucinous, cribriform, signet ring, medullary, 
and poorly differentiated,) according to WHO 2010 
[20]. The presence or absence of necrosis (focal and 
diffuse) was recorded. As regards, intratumoral 
lymphocytic infiltration, the presence of small round 
lymphocytes within neoplastic epithelial cells was 
divided into mild to moderate (up to three 
intraepithelial lymphocytes (IEL)/HPF) and marked (> 
3 IEL/HPF) according to the CAP guidelines [9]. The 
presence of peritumoral lymphocytic reaction requires 
2 or more large lymphoid aggregate. The lab rules 
include written informed consents of all patients and 
approval of using their specimen for research 
purposes. 
 
 Immunohistochemistry 
 IHC examination was performed using a 
Ventana Benchmark Ultra machine automated 
staining system. A four-antibody panel of MMR 
proteins, including MLH1, MSH2, MSH6, and PMS2, 
are conducted. The primary antibodies used were: 
anti MLH-1 (M1) Mouse Monoclonal Primary Antibody 
1.4 μg/ml) (Ventana, Tucson, AZ, USA), MSH2 
(G219-1129), Mouse Monoclonal Primary Antibody 
3.04 μg/ml) (Ventana, Tucson, AZ, USA), anti MSH6 
(44) Mouse Monoclonal Primary Antibody 0.101 
μg/ml) (Ventana, Tucson, AZ, USA), and PMS2 
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(EPR3947, Rabbit Monoclonal Primary Antibody 
11.84 μg/ml) (Ventana, Tucson, AZ, USA). Adjacent 
normal colonic epithelium, lymphocytes, and stromal 
cells served as positive internal controls; we use it to 
check for accuracy. Positive external controls from 
CRC positive for MLH-1, MSH-2, MSH-6, and PMS2 
are used. Negative controls were done by replacing 
the primary antibody with PBS. 
 According to the CAP protocol for 
immunohistochemistry interpretation, any nuclear 
staining even patchy is taken as “no loss of 
expression” (Figure 1: C, D, E, and F; Figure 2: C and 
F). Only absolute absence of nuclear staining was 
considered “loss of expression” (Figure 2: D and E) 
provided that internal controls are positive. Hence, 
carcinoma was considered MSI when nuclear staining 
was absent for at least one protein [21]. MSI-positive 
markers were reexamined to confirm the results. 
 In the present study, expression of proteins 
was then grouped into 10 categories (A-J) Table (1 
and 2): A) no loss of expression; B) loss of expression 
of all four proteins; C) combined loss of MLH1/PMS2; 
D) combined loss of MSH2/MSH6; E) combined loss 
of MSH6/PMS2; F) combined loss of MLH/MSH2 and 
isolated loss of any of the four proteins G: MLH1; H) 
MSH2; I) MSH6 and J) PMS2. 
 MSI-H is considered when two or more 
markers are demonstrated to be unstable (lost 
expression). MSI- low is considered when only one 
marker is unstable. MSS is the case when no markers 
are unstable. We follow Fujiyoshi et al., 2017 study 
definition of MSI that was approved for Bethesda [2], 
[22]. In Fujiyoshi et al., 2017 study, they include MSI-L 
as MSS. However, in our study, we constellate the 
results of expression of the 4 markers into 3 
categories (MSS, MSI-L, and MSI-H). 
 
 Statistical Analysis  
 All statistical analysis is done with the SPSS 
version 20 software program. Categorical data 
obtained are statistically evaluated using the X
2
 test. 
Whereas the only continuous data in the study (age) 
is evaluated using Mean ± stander deviation. The 
tests are considered statistically significant when the 
P value less than 0 .05. All clinicopathological 
parameters of the studied cases are tested for 
association with the results of expression of the four 
markers and the status of MSI (Table 1, 2, 3, and 4). 
Then all candidate predictors with a P < 0.05 in 
univariate analysis are included in a multivariate 
logistic regression model in an attempt to discover the 
factors predicting CRC with MSI. In this study, we use 
the MSI-H model as a reference model (Table 5).  
 
 
 
Results 
 
 A group of 115 cases of CRC are included in 
this study: 72 male and 43 females. The mean age of 
the patients was 50.88 ± 14.14 years, with an age 
range of 15-82 years. 72.2% of the cases (n = 83) are 
adenocarcinoma (NOS) Figure 1A, 24.3% of the 
cases (n = 28) are mucinous carcinoma Figure 2A, 
and 3.5% of the cases (n= 4) are signet ring 
carcinoma. All the assessed clinicopathological 
parameters categories are illustrated and correlated 
with the pattern of expression of the 4 markers of MSI 
(A-J) (Table 1, and 2) and the status of MSI (MSS, 
MSI-L, and MSI-H) (Table 3, and 4). The significance 
of the clinicopathological parameters as predictors of 
MSI-H is illustrated in Table 5. 
Table 1: Expression pattern of MMR protein and 
clinicopathological characteristics of CRC 
   
MSS 
(38) 
MSI 
(77) 
 
  
 A B C D E F G H I J 
P 
n 38 1 29 22 1 1 4 7 9 3 
Gender 
M 
n 25 0 18 14 0 1 2 5 5 2 
0.84 
% 66 0 62 64 0 100 50 71 56 67 
F 
n 13 1 11 8 1 0 2 2 4 1 
% 34 100 38 36 100 .0 50 29 44 33 
Age 
< 50 
n 17 1 13 13 1 1 2 2 2 1 
0.51 
% 45 100 45 59 100 100 50 29 22 33 
< 50 
n 21 0 16 9 0 0 2 5 7 2 
% 55 0 55 41 0 0 50 71 78 67 
 R 
n 16 1 22 18 1 0 3 3 8 1 
0.014* 
% 42 100 76 82 100 0 75 43 89 33 
L L 
n 22 0 7 4 0 1 1 4 1 2 
% 57.9 0 24 18 0 100 25 57.1 11.1 66.7 
LVE 
A 
n 30 1 19 10 1 0 1 4 9 2 
0.035* 
% 79 100 66 46 100 0 25 57 100 67 
P 
n 8 0 10 12 0 1 3 3 0 1 
% 21 0 34 54 0 100 75 43 0 33 
PNI 
A 
n 34 1 29 17 1 0 4 7 9 3 
0.012* 
% 89.5 100 100 77 100 0 100 100 100 100 
P 
n 4 0 0 5 0 1 0 0 0 0 
% 10.5 0 0 23 0 100 0 0 0 0 
G 
G2 
n 30 0 20 9 1 0 4 5 7 3 
0.033* 
% 79 0 69 41 100 0 100 71 78 100 
G3 
n 8 1 9 13 0 1 0 2 2 0 
% 21 100 31 59 0 100 0 29 22 0 
T 
T2 
n 6 0 7 3 1 0 0 3 0 0 
0.013* 
% 16 0 24 14 100 0 0 43 0 0 
T3 
n 31 1 20 17 0 0 4 4 9 3 
% 82 100 69 77 0 0 100 57 100 100 
T4 
n 1 0 2 2 0 1 0 0 0 0 
% 3 0 7 9 0 100 0 0 0 0 
N 
N0 
n 20 0 23 11 1 0 1 5 9 2 
0.000* 
% 53 0 79 50 100 0 25 71 100 67 
N1 
n 5 1 4 10 0 0 3 2 0 1 
% 13 100 14 45 0 0 75 29 0 33 
N2 
n 13 0 2 1 0 1 0 0 0 0 
% 34 0 7 4 0 100 0 0 0 0 
V 
NOS 
n 31 1 21 10 1 0 4 5 7 3 
0.3 
% 81 100 72 45 100 0 100 72 78 100 
MUC 
n 6 0 8 10 0 1 0 1 2 0 
% 16 0 28 46 0 100 0 14 22 0 
Sign. 
n 1 0 0 2 0 0 0 1 0 0 
% 3 0 0 9 0 0 0 14 0 0 
G: Gender; L: Laterality; LVE: Lymphovascular Emboli; PNI: perineural Invasion; T: T 
stage; N: Nodal stage; V: Histopathologic variant; NOS: Non otherwise specified; and 
MUC: Mucinous; sign: signet ring; A: no loss of expression of any marker; B: loss of 
expression of all markers; C: loss of expression of both MLH, and PMS2; D: loss of 
expression of both MSH2, and MSH6; E: loss of expression of both of MSH6, and PMS2; 
F: loss of expression of both of MLH, and MSH2; G: isolated loss of expression of MLH; H: 
isolated loss of expression of MSH2; I: isolated loss of expression of MSH6; J: isolated 
loss of expression of PMS2. 
 
 Expression pattern of MMR protein, 
 clinicopathological and histopathological 
 characteristics of CRC (Table 1, and 2)  
 A total of 72 males and 43 females were 
enlisted in the study. Age of the cases was 
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subgrouped into < 50 (53 cases) and ≥ 50 years (62 
cases). Eighty-three cases were of adenocarcinoma 
NOS, 28 cases were of the mucinous type, and 4 
cases were of signet ring type. The clinicopathological 
characteristics of each expression pattern of MMR 
proteins are included in Table 1. 
Table 2: Expression pattern of MMR protein and 
histopathological characteristics of CRC 
  
 A B C D E F G H I J 
P 
n. 38 1 29 22 1 1 4 7 9 3 
Mucinous 
component 
Absent 
n 26 1 13 7 0 0 2 5 4 2 
0.353 % 68 100 45 32 0 0 50. 72 44 67 
<10% 
n 3 0 3 1 0 0 1 0 2 0 
% 8 0 10 5 0 0 25. 0 22 0 
 
10-50% 
n 3 0 6 4 1 0 1 1 1 1 
% 8 0 21 18 100 0 25 14 11. 33 
≥50% 
n 6 0 7 10 0 1 0 1 2 0 
% 16 0 24 50 0 100 0 14 22 0 
Signet ring 
component 
A 
n 36 1 28 19 1 0 4 6 9 3 
0.041* 
% 95 100 97 86 100 0 100 86 100 100 
P 
n 2 0 1 3 0 1 0 1 0 0 
% 5 0 3 14 0 100 0 14 0 0 
TIL 
Absent 
n 27 0 15 8 1 1 0 3 2 1 
0.012* 
% 71 0 52 36 100 100 0 43 22 33 
Mild 
n 11 1 14 14 0 0 4 3 7 2 
% 29 100 48 64 0 0 100 43 78 67 
Marked 
n 0 0 0 0 0 0 0 1 0 0 
% 0 0 0 0 0 0 0 14 0 0 
PTL 
Absent 
n 38 0 26 18 1 1 4 5 9 2 
0.009* % 100 0 90 82 100 100 100 71 100 67 
Present 
n 0 1 3 4 0 0 0 2 0 1 
% 0 100 10 18 0 0 0 29 0 33  
Necrosis 
Absent 
n 10 0 11 2 0 0 1 2 4 0 
0.172 
% 26 0 38 9 0 0 25 29 44 0 
Focal 
n 23 0 15 13 1 1 3 5 5 3 
% 61 0 52 59 100 100 75 71 56 100 
Diffuse 
n 5 1 3 7 0 0 0 0 0 0 
% 13 100 10 32 0 0 0 0 0 0 
TIL: tumour infiltrating lymphocyte; PTL: peritumoral lesion; A: no loss of expression of any 
marker; B: loss of expression of all markers; C: loss of expression of both MLH, and 
PMS2; D: loss of expression of both MSH2, and MSH6; E: loss of expression of both of 
MSH6, and PMS2; F: loss of expression of both of MLH, and MSH2; G: isolated loss of 
expression of MLH; H: isolated loss of expression of MSH2; I: isolated loss of expression 
of MSH6; J: isolated loss of expression of PMS2. 
 
 A (No loss of expression of any MMR 
 proteins): (38 cases) (Figure 1: C, D, E, F)  
 Around 66% of the cases of this pattern are 
made with 55% of them ≥ 50 years old, and 58% left-
sided. Most of the cases of this pattern reveal no 
lymphovascular emboli (LVE) (79%), no perineural 
invasion (PNI) (90%), grade 2 (79%), stage T3 (82%), 
stage N0 (53%), and of adenocarcinoma NOS (81%). 
Most of the cases of this pattern do not have a 
mucinous component (68%), or signet ring component 
(95%), or TIL (71%), or PTL (100%) and show focal 
necrosis in 61% of the cases. 
 
 B (loss of expression of all MMR proteins) 
 Only one female case, 30 years old, has right-
sided cancer colon. It is of adenocarcinoma NOS G3, 
stage T3N1, and doesn’t have LVE, or PNI, mucinous 
or signet ring component. It shows mild TIL, PTL, and 
diffuse necrosis.  
 
 C (combined loss of expression of MLH 
 and PMS2 proteins): (29 cases)  
 Around 62% of the cases of this pattern are 
male. 55% of them are ≥ 50 years old. 76% is the right 
side. Most of the cases of this pattern do not have 
LVE (66%), or PNI (100%). They are of grade 2 
(69%), stage T3 (69%), and stage N0 (97%). Most of 
them are either of adenocarcinoma NOS or mucinous 
carcinoma (72%, 28% respectively). Some of the 
cases in this pattern are associated with absence of 
the mucinous component, or mucinous component ≥ 
50% (45%, 21% respectively), absence of signet ring 
component (95%), TIL (absent, mild) (52%, 48% 
respectively), and absence of PTL (90%) and show 
focal necrosis in 52% of the cases. 
 
Figure 1: Colonic adenocarcinoma, moderately differentiated, grade 
II; A) H&E (x 40), Distorted acini of moderately differentiated 
malignant cells; B) H&E (x 400), showing TIL (blue arrow). PTL 
(black arrow); C) MLH1, moderately positive nuclear staining of 
tumor cells (x 40), Inset (x400); D) MSH2, moderately positive 
nuclear staining of tumor cells (x 100); E) MSH6 (x 100), moderately 
positive nuclear staining of tumor cells (x 100); F) PMS 2(x100), 
moderately positive nuclear staining of tumor cells (x 100) 
 
 
 D (combined loss of expression of MSH2 
 and MSH6 proteins): (22 cases) (Figure 2: 
 D, and E) 
 Around 64% of the cases of this pattern are 
male. 59% of them are < 50 years old. 82% is the right 
side. Most of the cases of this pattern reveal the 
presence of LVE (54%) and absence of PNI (77%). 
Most of them are grade 3 (59%), stage T3 (77%), and 
stage N0 (50%). They are of adenocarcinoma NOS, 
mucinous carcinoma, and signet ring carcinoma (45%, 
46%, and 9% respectively). This pattern in most of the 
cases is associated with the presence of mucinous 
component ≥ 50% in 50% of the cases in this pattern. 
There is no signet ring component in 86% of the 
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cases of this pattern. TIL (absent, mild) is present in 
36%, 64% of this pattern, respectively (Figure 1B, and 
2B). Absence of PTL is evidenced in 82% of the cases 
in this pattern. It shows focal necrosis in 59% of the 
cases. 
 
Figure 2: Colonic mucinous carcinoma; A) H&E (x 100), Pools of 
mucin entangling malignant glands; B) H&E (x 400), TIL (blue 
arrows); PTL (black arrow); C) MLH 1; Weakly positive nuclear 
staining of tumor cells (x 400), with positive lymphocytes, internal 
control; D) MSH2, Negative nuclear staining of tumor cells (x 400). 
with positive lymphocytes, internal control; E) MSH6, Negative 
nuclear staining of tumour cells (x 40); F) PMS 2, Weakly positive 
staining of tumour cells (x 400) 
 
 E (combined loss of expression of 
 MSH6and PMS2 proteins) 
 Only one female case, 35-years-old, has 
right-sided CRC. It is of adenocarcinoma G2, stage 
T2N0, and has LVE, PNI, mucous component 20%, 
signet ring component, and focal necrosis. It doesn’t 
show TIL or PTL.  
 
 F (combined loss of expression of MLH 
 and MSH2 proteins) 
 Only one male case, 24years old, has left-
sided CRC. It is of mucinous carcinoma G3, stage 
T4N2b, and has LVE, PNI, mucous component 60%, 
signet ring component, and focal necrosis. It doesn’t 
show TIL or PTL.  
 G (Isolated loss of expression of MLH1): (4 
 cases) 
 In 4 cases, 2 of them are male, 2 of them are 
< 50 years old. 3/4 cases are left sided. Most of the 
cases of this pattern reveal LVE (75%), no PNI 
(100%), grade 2 (100%), stage T3 (100%), stage N1 
(75%), and of adenocarcinoma NOS (100%). This 
pattern in most of the cases have mucinous 
component <50%, no mucinous component, (50%, 
50% respectively), no signet ring component (100%), 
or TIL (mild) (100%), or no PTL (100%) and show 
focal necrosis in 75% of the cases. 
 
 H (Isolated loss of expression of MSH2): (7 
 cases) 
 In 7 cases, 5 of them are male, 5 of them are 
≥ 50 years old. 4 cases are left sided. Most of the 
cases of this pattern reveal no LVE (57%), no PNI 
(100%). They are of grade 2 (71%), stage T3 (57%), 
and stage N0 (71%), and adenocarcinoma NOS 
(72%). Most of the cases in this pattern are 
associated with the absence of mucinous component 
(72%), absence of signet ring component (86%), TIL 
(absent, mild) (43% each), absence of PTL (71%) and 
show focal necrosis in 71% of the cases. 
 
 I (Isolated loss of expression of MSH6): (9 
 cases) 
 In 9 cases, 5 of them are male, 7 of them are 
≥ 50 years old, 8 cases are right sided. Most of the 
cases of this pattern reveal no LVE (100%), no PNI 
(100%), grade 2 (78%), stage T3 (100%), stage N0 
(100%), and of adenocarcinoma NOS (78%). This 
pattern in most of the cases is associated with no 
mucinous component, mucinous component ≥ 50%, 
mucinous component < 10%), (44%, 22%, 22% 
respectively), no signet ring component (100%), TIL 
(mild) (78%), and no PTL (100%). It shows focal 
necrosis in 56% of the cases. 
 
 J (Isolated loss of expression of PMS2): (3 
 cases)  
 In 3 cases, 2 of them are male. 2 of them are 
≥ 50 years old. 2cases are left sided. Most of the 
cases of this pattern reveal no LVE (67%), no PNI 
(100%). They are of G2 adenocarcinoma (NOS) stage 
T3 (100%), and stage N0 (67%). This pattern in most 
of the cases is associated with the absence of 
mucinous component (67%), absence of signet ring 
component (100%), mild TIL (67%), and absence of 
PTL (67%). It shows focal necrosis in 100% of the 
cases. In the present study, there is significant 
association of expression pattern of MMR proteins 
with the laterality, the presence of lymphovascular 
emboli, the presence of perineural invasion, grade, T 
stage, N stage, the presence of signet ring 
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component, and the extent of tumour-infiltrating 
lymphocyte, the presence of peritumoral lesion (0.014, 
0.035, 0.012, 0.033, 0.013, 0.000, 0.041, 0.012, and 
0.009 respectively). No significant association of 
expression pattern of MMR proteins with gender, age 
category, histopathological type, the presence and 
amount of mucinous component, or necrosis (0.84, 
0.51, 0.3, 0.35, 0.17 respectively). 
Table 3: Clinicopathological characteristics about the MSI 
status of CRC 
  
 MSS MSI-L MSI-H P 
n 38 (33%) 23 (20%) 54 (47%) 115 
Gender 
M 
n 25 14 33 
088 
 
% 66 61 61 
F 
n 13 9 21 
% 34 39 39 
Age 
< 50 
n 17 7 29 
0.169 
% 45 30 54 
< 50 
n 21 16 25 
% 55 70 46 
 R 
n 16 15 42 
0.002* 
 
% 42 65 78 
L L 
n 22 8 12 
% 58 35 22 
LVE 
A 
n 30 16 31 
0.092 
% 79 70 57 
P 
n 8 7 23 
% 21 30 43 
PNI 
A 
n 34 23 48 
 
0.253 
 
% 90 100 99 
P 
n 4 0 6 
% 10 0 11 
G 
G2 
n 30 19 30 
0.016* 
% 79 83 56 
G3 
n 8 4 24 
% 21 17 44 
T 
T2 
n 6 3 11 
0.324 
 
% 16 13 21 
T3 
n 31 20 38 
% 81 87 70 
T4 
n 1 0 5 
% 3 0 9 
N 
N0 
n 20 17 35 
0.001* 
% 53 74 65 
N1 
n 5 6 15 
% 13 26 28 
N2 
n 13 0 4 
% 34 0 7 
V 
NOS 
n 31 19 33 
0.146 
% 81 83 61 
MUC 
n 6 3 19 
% 16 13 35 
Signet 
n 1 1 2 
% 3 4 4 
G: Gender; L: Laterality; LVE: Lymphovascular Emboli; PNI: perineural Invasion; T: T stage; N: Nodal stage; 
V: Histopathologic variant; NOS: Non otherwise specified; and MUC: Mucinous. 
 
 
 Clinicopathological and histopathologic 
 characteristics about the MSI status  of 
 CRC (Table 3, and 4) 
 MSI status of the CRC in our study is 
subdivided into 3 groups (MSS (38 cases), MSI-L (23 
cases), and MSI-H (54 cases). Table 3 and 4 illustrate 
the clinicopathological and histopathological 
characteristics of each category of MSI. 
 
 MSS (microsatellite stable CRC) 
 About 66% of the cases of this group are 
male. 55% of them are ≥ 50 years old, 58% are left 
sided. Most of the cases of this status are 
characterised by the absence of LVE (79%), and 
absence of PNI (90%). They are of grade 2 (79%), 
stage T3 (82%), and stage N0 (53%). 81% of the 
cases in this status are of adenocarcinoma NOS. 
Most of the cases in this status do not have either 
mucinous component (68%), or signet ring component 
(95%), nor TIL (71%), nor PTL (100%). It shows focal 
necrosis in 61% of the cases. 
Table 4: Histopathological characteristics of the MSI status of 
CRC 
  
 MSS L MSI H MSI P 
n. 38 23 54 115 
Mucinous 
component 
Absent 
n 26 13 21 
0.089 
 
% 68 57 40 
<10% 
n 3 3 4 
% 8 13 7 
10-50% 
n 3 4 11 
% 8 17 20 
≥50% 
n 6 3 18 
% 16 13 33 
Signet ring 
component 
A 
n 36 22 49 
0.653 
 
 
% 95 96 91 
P 
n 2 1 5 
% 5 4 9 
TIL 
Absent 
n 27 6 25 
0.004* 
% 71 26 46 
Mild 
n 11 16 29 
% 29 70 54 
Marked 
n 0 1 0 
% 0 4 0 
PTL 
Absent 
n 38 20 46 
0.048* 
 
% 100 87 85 
Present 
n 0 3 8 
% 0 13 15 
Necrosis 
Absent 
n 10 7 13 
0.23 
% 26 30 24 
Focal 
n 23 16 30 
% 61 70 56 
Diffuse 
n 5 0 11 
% 13 0 20 
TIL: tumour infiltrating lymphocyte; PTL: peritumoral lesion. 
 
 
 MSI-L (low microsatellite instability CRC) 
 About 61% of the cases of this group are 
male, 70% of them are ≥ 50 years old, 65% are right 
sided. Most of the cases of this status are 
characterised by the absence of LVE (70%), and 
absence of PNI (100%). They are of grade 2 (83%), 
stage T3 (87%), and stage N0 (74%). 83% of the 
cases in this status are of adenocarcinoma NOS. the 
mucinous component in this status ranges from 0, < 
10%, 10-50%, and ≥ 50% in 57%, 13%, 17%, 13% of 
the cases respectively. It is characterised by the 
absence of signet ring component (96%), mild TIL 
(70%), and absence of PTL (87%). It shows focal 
necrosis in 70% of the cases. 
 
 MSI-H (high microsatellite instability CRC) 
 Around 61% of the cases of this group are 
male, 54% of them are < 50 years old, 78% are right 
sided. Most of the cases of this status are 
characterised by the absence of LVE (57%), and 
absence of PNI (89%). They are of grade 2, 3(56%, 
44% respectively), stage T3 (70%), and stage N0 
(65%). They are of adenocarcinoma NOS, mucinous, 
and signet ring carcinoma (61%, 35%, and 4% 
respectively). The mucinous component in this status 
ranges from 0, < 10%, 10-50%, and ≥ 50% in 40%, 
7%, 33%, and 20% of the cases respectively). It is 
characterised by the absence of signet ring 
component (91%), mild TIL (54%), and absence of 
PTL (85%). It shows focal necrosis in 56% of the 
cases. 
 In the present study, there is a significant 
association of MSI status with the laterality, grade, N 
stage, the presence and grade of tumour-infiltrating 
lymphocyte, the presence of a peritumoral lesion 
(0.002, 0.016, 0.001, 0.004, and 0.048 respectively). 
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No significant association of MSI status with gender, 
age category, the presence of lymphovascular emboli, 
the presence of perineural invasion, T stage, 
histopathological type, extent of mucinous component, 
the presence of signet ring component or necrosis 
(0.88, 0.16, 0.09, 0.25, 0.32, 0.14, 0.08, 0.65, and 
0.23 respectively). 
 
 Multivariate analysis of factors predicting 
 CRC with MSI-H (Table 5) 
 Multivariate logistic regression analysis was 
conducted including all of the above candidate 
predictors (laterality, grade, N stage, the extent of 
tumour-infiltrating lymphocyte, the presence of 
peritumoral lesion that is significant at univariate 
analysis). Proximal location (right sided) and lower 
grade, higher nodal stage, and marked TIL are 
selected as predictors of MS-H CRC when compared 
to the model of MSS based on a P < 0.05 (0.005, 
0.031, 0.025, and 0.000 respectively). However, lower 
grade only is subsequently selected as predictors of 
MSI-H when compared to MSI-L based on a P < 0.05 
(0.027). The final model of MSI-H predictors is shown 
in Table 5. 
Table 5: Multivariate analysis of factors predicting CRC with 
MSI-H Parameter Estimates 
MSI 
a
 B Std. Error Sig. 
95% Confidence Interval for Exp (B) 
Lower Bound Upper Bound 
MSS 
Intercept 1.541 390.22 0.997   
laterality -1.466- 0.526 0.005 0.082 0.646 
grade 1.279 0.594 0.031 1.121 11.516 
N stage -1.892- 0.847 0.025 0.029 0.793 
TIL -13.860- 0.527 0.000 3.404E-007 2.686E-006 
MSI-L 
Intercept 3.910 2550.3 0.999   
grade 1.551 0.701 0.027 1.194 18.625 
a: the reference category is MSI-H; TIL: tumour infiltrating lymphocyte; N: nodal stage. 
 
 
 
Discussion 
 
 The annual incidence of CRC worldwide 
raises a significant public health impact. Familial CRC 
represents 20% of all CRC. Lynch syndrome 
represents 3.5% of all CRC [23]. These figures, 
besides awareness of the role of genomic instability in 
initiation and progression in CRC, raise the need for 
molecular screening of all CRC for Lynch syndrome 
[14]. Hashmi et al., 2017 reported that PCR 
amplification of microsatellite repeats remain the gold 
standard for recognition of MSI phenotype, this 
approach is not feasible in routine pathology lab [9], 
[24]. Therefore Hampel 2018 study recommends that 
IHC is preferred a method to screen for LS as IHC is 
equally sensitive to PCR, inexpensive, more readily 
available, and predicts the nonworking gene, so it has 
a big role in limiting the number of the gene to be 
sequenced [24]. Hampel 2018 study recommendation 
confirms the previous conclusion of the national 
cancer institute workshop on microsatellite instability 
for cancer detection and Familial Predisposition [22], 
[24]. 
 The presence of MSI defines a subset of 
colorectal carcinomas with special molecular aetiology 
and characteristic clinicopathological features 
inclusive of increased survival [9], [15]. Since MSI-H 
CRCs share some morphological features such as 
young patient age, right-sided location, mucinous and 
signet ring histology, and intratumoral lymphocytosis, 
careful observation of tumour histology help 
identifying these tumours [19]. Thomas, in his study, 
concluded that quantification of TILs might provide a 
simple, single criterion for choosing CRC patients as 
candidates for MSI testing [25]. 
 
 Frequency of expression pattern of MMR 
 proteins and MSI status of CRC (Table 1, 2, 
 3, and 4) 
 In our study, the frequency of MSI (low and 
high) is 67% of CRC cases of the study (Table 3). 
MSI-L account for 20% of CRC cases of the study. 
MSI-H account for 47% of CRC cases of the study. 
The frequency of loss of expression is found to be 
quite variable in different studies. Tumours with d 
MMR status accounted for 34% of the total study 
cases that was done on the Pakistani population [9]. 
21% in Singapore population [26], 6.9% in Chinese 
population [27] and approximately 15% in western 
studies [28]. The higher frequency of MSI in cases of 
CRC of our study compared to the previous studies in 
the same issue is attributed to that the pathology lab 
that we retrieve the cases from it is the unique lab if 
not the only lab in investigation of the expression of 
MMR protein by immunohistochemistry at this time, so 
the cases, expected clinically to have MSI, are 
transferred to this lab for immunohistochemical 
investigation for MMR protein.  
 In our study, the expression pattern of the d 
MMR proteins has variable patterns. No loss of 
expression of MMR proteins (MSS) accounts for 33% 
of the study cases. However, MSI includes all other 
patterns of lost expression. Loss of expression of all 
MMR proteins (MLH, MSH2, MSH6, and PMS2) is 
present in one case of the study (0.12% of MSI). The 
combined loss of 2 MMR proteins includes 4 
categories the most frequent in our study is combined 
loss of MLH, and PMS2 29/115 (38% of MSI) then 
combined loss of MSH2, and MSH6 22/115 (29% of 
MSI). The other 2 categories of the combined loss of 2 
MMR proteins include only 2 cases (one for each 
category (MLH + MSH2); (MSH6 + PMS2)) each 
represents 0.12% of MSI cases of the study. These 
frequencies as regard combined loss of MMR proteins 
are in agreement to studies done on Pakistani and 
Shanghai population [9], [11]. Isolated loss of one 
MMR proteins (MSI-L) accounts for 23/115 (30% of 
MSI). Lost MLH expression is present in 4/115 (5% of 
MSI). Lost MSH2 expression is present in 7/115 (9% 
of MSI). Lost MSH6 expression is present in 9/115 
Basic Science 
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(12% of MSI). Lost PMS2 expression is present in 
3/115 (4% of MSI). This means that the most frequent 
isolated loss of one MMR proteins in our study is lost 
MSH6, followed by MSH2 then MLH1, and lastly 
PMS2.  
 These results are in agreement with Yuan et 
al., 2015 as regard MSH6 and PMS2 [11]. Yuan et al., 
2015 reported and confirmed that MMR gene products 
existing in cells always stay as heterodimers complex. 
And MLH1 and MSH2 are obligatory partners, 
combined with their secondary partners PMS2 and 
MSH6 respectively. If the degradation of the former 
partners occurs, caused by the mutation of the 
respective MMR gene, the later partners will not exist 
anymore. But the reverse is not true [11]. This fact 
was applied by Hall et al., in his study and screened 
CRC using MSH6, PMS2 proteins only instead of 4 
[29]. This means that it is unlogic to find the isolated 
loss of PMS2 alone without loss of MLH1. However, 
4% of MSI in our study, and 9.6% of Kumar et al., 
2018 study showed isolated loss of PMS2 without loss 
of the MLH1 [30]. Hashmi et al., 2017 study found an 
isolated loss of MLH1 in 5% of study cases which 
agree with our result as regard isolated loss of MLH1 
(5% of MSI) [9]. This controversy between our results 
and Yuan et al., 2015 can be explained on the basis 
that some pathogenic MLH1 missense mutations or 
MLH1 promotor hypermethylation functionally 
inactivates MLH1 protein and preserve its antigenicity 
leading to the occurrence of isolated loss of PMS2 
[31], [32]. Hashmi et al., 2017 study, like our study, 
showed isolated loss of MLH1 (without its secondary 
partner) in 5% of the studied cases of CRC [9]. The 
frequent failure of antigenic retrieval of MLH1 protein 
is the logic cause for the lower frequency of isolated 
loss of MLH1 compared to other studies the problem 
that similarly faces Yuan et al., 2015 study [11]. 
 
 Correlation of Expression pattern of MMR 
 protein/MSI status with clinicopathological 
 and histopathological characteristics of 
 CRC 
 The biological explanations for the 
characteristic morphology of MSI-H colorectal cancer 
are not known [33]. However, the increased 
lymphocytic reaction in MSI-H colorectal cancer may 
be explained by stimulated immunogenicity 
associated with the generation of abnormal proteins 
transcribed from mutant genes [15], [33]. In our study, 
there is significant correlation of expression pattern of 
MMR proteins with the laterality, lymphovascular 
emboli, perineural invasion, grade, T stage, N stage, 
signet ring component, tumor infiltrating lymphocyte, 
and peritumoral lesion (0.014, 0.035, 0.012, 0.033, 
0.013, 0.000, 0.041, 0.012, and 0.009 respectively) 
Table (1, 2). These mean that lost expression of MMR 
proteins (MSI-L, MSI-H) in our study commonly occurs 
in the proximal colon up to the splenic flexure, and 
significantly characterized by the presence of 
lymphovascular emboli, absence of perineural 
invasion, lower grade, higher T stage, lower N stage, 
the presence of signet ring component, mild to 
marked tumor infiltrating lymphocyte, and the 
presence of peritumoral lesion. While no loss of 
expression of any MMR proteins (MSS) commonly 
occurs in the distal colon and rectum, associated with 
the absence of lymphovascular emboli, presence of 
perineural invasion, lower T stage, higher N stage, 
absence of signet ring component, absence of tumour 
infiltrating lymphocyte, and peritumoral lesion.  
 These results are approving nearly all studies 
dealt with this issue [9], [11], [19], [27], [34], [35], [36]. 
But we are different from most of the studies as to 
regard the extent of mucinous component and the 
presence of signet ring component that show no 
significant correlation with MSI status of the tumour in 
our study (Table 4) [27], [34], [36]. However Hashmi et 
al., 2017 and Yuan et al., 2015 studies agree with our 
result in failure of detection of significant correlation of 
MSI status of CRC and the extent of mucinous and 
signet ring component of the tumour [9], [11]. This 
limited detection of the mucinous and signet ring 
component can be explained by examination of one 
slide per case so the exact amount of both 
components cannot be detected at the research level 
but if assessed in routine examination of the slides 
during the initial diagnosis of the mother, the father 
will be more accurate in prediction of MSI status of 
CRC. But it puts a big burden on the pathologists. 
 
 Multivariate analysis of factors predicting 
 CRC with MSI-H (Table 5) 
 The current study succeeds in confirmation of 
that proximal colon CRC, and the presence of marked 
TIL, lower grade and higher nodal stage have a 
significant predictive value of MSI-H as compared to 
MSS CRC. While only lower grade has a significant 
predictive value of MSI-H when compared to MSI-L 
CRC. This result when MSI-H model is taken as a 
reference model.  
 There is a failure of confirmation of some 
clinicopathological and histopathological parameters 
as significant predictors of MSI-H that previously 
reported in the previous models of MSI-H predictors 
such as age, mucinous component, and signet ring 
component [33], [37], [38]. The reasons behind these 
controversies with our study are in different cut off 
value used for any of the clinicopathological 
parameters investigated or inclusion of additional 
parameters in these studies. For instance, Greenspan 
et al., 2009 considered any mucinous differentiation, 
no matter what the overall percentage rather than 
having at least 50% mucinous differentiation. While in 
our study, we consider the percentage of the 
mucinous component. Also, their models included 
histologic heterogeneity and the type of growth pattern 
that they are not included in our study [37]. Jenkins et 
al., 2007 had much younger patients, which probably 
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enriched the number of HNPCC cases in their study 
[33]. Revised Bethesda Guidelines for Microsatellite 
Instability included the Presence of synchronous, 
metachronous colorectal or other HNPCC-associated 
tumours regardless of age [38]. The big obstacle of 
our study is the inability to investigate germline 
mutations of MMR genes for this large number of 
cases. However, our study cases are not selected 
according to their ages, so the effectiveness of the 
clinicopathological and histological parameters can be 
noticed accurately. 
 In conclusion, the prevalence of MSI in our 
study is relatively high in comparison to international 
literature. Although they add a big burden on the 
pathologists, all clinicopathological and histological 
parameters should be assessed in all CRC for the 
sake of predicting MSI. Since it is not applicable to 
test all cases of CRC for MSI, selected cases only 
(according to clinicopathological predictors) will be 
proceeded to IHC for MLH1, MSH2 only. 
Consequently, the optimal approach to MSI evaluation 
is the immunohistochemical (IHC) analysis of 
tumours, followed by germline MSH2/MLH1 testing. 
IHC is easily available and inexpensive as part of the 
routine services inthe department of pathology. 
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